Presbyopia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Presbyopia - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Presbyopia: Overview
Presbyopia is the gradual loss of eyes' ability to focus on nearby objects. It's a natural part of aging. Common symptoms of presbyopia are eyestrain or headaches after reading or doing close work, difficulty reading small print, fatigue from doing close work, overall problems seeing and focusing on objects that are close, or squinting. Presbyopia is diagnosed by a basic eye exam, which includes a refraction assessment and an eye health exam. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Treatment options include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.
'Presbyopia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Presbyopia Emerging Drugs
Further product details are provided in the report……
Presbyopia: Therapeutic Assessment
This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:
Presbyopia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.
Presbyopia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Presbyopia - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Presbyopia: Overview
Presbyopia is the gradual loss of eyes' ability to focus on nearby objects. It's a natural part of aging. Common symptoms of presbyopia are eyestrain or headaches after reading or doing close work, difficulty reading small print, fatigue from doing close work, overall problems seeing and focusing on objects that are close, or squinting. Presbyopia is diagnosed by a basic eye exam, which includes a refraction assessment and an eye health exam. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Treatment options include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.
'Presbyopia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve Presbyopia.
This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Presbyopia Emerging Drugs
- AGN-190584: AbbVie
- BRIMOCHOL: Visus Therapeutics
Further product details are provided in the report……
Presbyopia: Therapeutic Assessment
This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Presbyopia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Presbyopia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.
Presbyopia Report Insights
- Presbyopia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Presbyopia drugs?
- How many Presbyopia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Presbyopia and their status?
- What are the key designations that have been granted to the emerging drugs?
- AbbVie
- Orasis Pharmaceuticals
- Eyenovia
- Aclaris Therapeutics
- Ocuphire Pharma
- Visus Therapeutics
- Ocularis Pharma
- Cellix Bio
- AGN-190584
- AGN-241622
- CSF-1
- ARVN-003
- Oxymetazoline
- Phentolamine/pilocarpine
- BRIMOCHOL
- Phentolamine
- CLX-OPH-561
Introduction
Executive Summary
Presbyopia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Presbyopia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
CSF-1: Orasis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
BRIMOCHOL: Visus Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
AGN-241622: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
CLX-OPH-561: Cellix Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Presbyopia Key Companies
Presbyopia Key Products
Presbyopia- Unmet Needs
Presbyopia- Market Drivers and Barriers
Presbyopia- Future Perspectives and Conclusion
Presbyopia Analyst Views
Appendix
Executive Summary
Presbyopia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Presbyopia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
CSF-1: Orasis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
BRIMOCHOL: Visus Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
AGN-241622: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
CLX-OPH-561: Cellix Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Presbyopia Key Companies
Presbyopia Key Products
Presbyopia- Unmet Needs
Presbyopia- Market Drivers and Barriers
Presbyopia- Future Perspectives and Conclusion
Presbyopia Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Presbyopia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Presbyopia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Presbyopia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Presbyopia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
